Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: Comparison to testosterone enanthate--a clinical research center study

Journal of Clinical Endocrinology and Metabolism

Volumn 80, Issue 12, 1995, Pages 3567-3575

  Salehian, Behrouz ^a   Wang, Christina ^a   Alexander, Gerianne ^b   Davidson, Tina ^a   McDonald, Veronica ^a   Berman, Nancy ^a   Dudley, Robert E ^c   Ziel, Frederick ^d   Swerdloff, Ronald S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW ORLEANS   (United States)

^c Bio Technology General Corporation   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE CYCLODEXTRIN; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; HYPOGONADISM; INTRAMUSCULAR DRUG ADMINISTRATION; LIBIDO; LUTEINIZING HORMONE BLOOD LEVEL; MALE; ORGASM; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ADULT; BLOOD; BLOOD CELL COUNT; CYCLODEXTRINS; DIHYDROTESTOSTERONE; ESTRADIOL; GONADOTROPINS; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; SEX HORMONE-BINDING GLOBULIN; SEXUAL BEHAVIOR; TESTOSTERONE;

ILEX COOKII;

EID: 0028788046     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.80.12.8530600     Document Type: Article

References (27)

1. Wilson JD. 1988 Androgen abuse by athletes. Endocr Rev. 9:181-199.
2. Cantrill JA, Davis P, Laya DM, Newman M, Anderson DC. 1984 Which testosterone replacement therapy?Clin Endocrinol (Oxf). 21:97-107.
3. Wang C, Swerdloff RS. 1991 Androgens. In: Smith CM, Raynand AM, eds.Textbook of pharmacology, Philadelphia: Saunders; 683-694.
4. Nieschlag E, Behre HM. 1990 Testosterone action, deficiency and substitution. Berlin: Springer-Velag.
5. de LormierA A, Gorday GS, Lower RC, Carbone JV. 1965 Methyltestosterone, related steroids, and liver function. Arch Intern Med. 116:289-294.
6. Skakkeback NE, Bancroft J, Davidson DW, Warner P. 1981 Androgen replacement with oral testosterone undecanoate in hypogo-nadal men: a double blind controlled study. Clin Endocrinol (Oxf). 14:49-61.
7. GoorenL JG. 1994 A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 15:212-215.
8. Fridlay JC, Place V, Snyder PJ. 1989 Treatment of primary hypogonadism in men by transdermal administration of testosterone. J Clin Endocrinol Metab. 68:369-373.
9. Ahmed SR, Boucher AE, Mairni A, Santen RJ, Bartholomew M, Demers LM. 1988 Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab. 66:646-651.
10. Meikle AW, Mazer NA, Moellmer JF, et al. 1992 Enhanced trans-dermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 74:623-628.
11. Uekama K, Otagiri M. 1987 Cyclodextrin in drug carrier systems. Crit Rev Ther Drug Carrier Syst. 3:1-40.
12. Brewster ME, Estes KS, Loftsson T, et al. 1988 Improved delivery through bilogical membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified b-cyclodextrin. J Pharm Sci. 77:981-985.
13. Stuenkel CA, Dudley RE, Yen SSC. 1991 Sublingual administration of testosterone-hydroxypropyl-b-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J Clin Endocrinol Metab. 72:1054-1059.
14. Kwan M, Greenleaf WJ, Mann J, Carpo L, Davidson JM. 1983 The nature of androgen action on male sexuality: a combined laboratory self-report study on hypogonadal men. J Clin Endocrinol Metab. 57:557-562.
15. Milliken GA, Johnson DE. 1984 Analysis of missing data. New York: Van Nostrand Reinhold; vol 1.
16. Roch GC, Landis JR, Freeman JL, Freeman DH, Lehnen RG. 1977 A general methodology for the analysis of experiments with repeated measurements of categorical data. Biometrics. 33:133-158.
17. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff R. 1982 Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 37:425-430.
18. Buena F, Swerdloff RS, Steiner BS, et al. 1993 Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril. 59:1118-1123.
19. GoorenL JG. 1987 Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav. 16:463-473.
20. O’Carroll R, Shapiro C, Bancroft J. 1985 Androgens, behavior and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf). 23:527-538.
21. Anderson R, Bancroft J, Wu F. 1992 The effects of exogenous testosterone on sexuality in men. J Clin Endocrinol Metab. 75:1503-1507.
22. Bagatell CJ, Herman JR, Matsumoto AM, Rivier JE, Bermner WJ. 1994 Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 79:561-567.
23. Friedl KE, Hannan CJ, Jones RE, Plymate SR. 1990 High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 39:69-74.
24. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ. 1992 Physiologic testosterone levels innonnal men suppress high-density lipoprotein cholesterol. Ann Intern Med. 116:967-973.
25. W HO. 1992 Guidelines for use of androgens in men. Geneva: WHO.
26. GregoryJ W, Greene SA, Thompson J, Scrimgeour CM, Rennie MJ. 1992 Effects of oral testosterone undecanoate on growth, body composition, strength and energy expenditure of adolescent boys. Clin Endocrinol (Oxf). 37:207-213.
27. Bulter GE, Sellar RE, Walker RF, Hendry M, Kelnar CJ, Wu FC. 1992 Oral testostrone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab. 75:37-44.